LPTX: Leap Tx Net earnings per share (EPS TTM)

Leap Therapeutics (LPTX) - corporate logo

High clinical trial costs are creating a liquidity deficit, yet future licensing deals with big pharma will drive explosive profit growth. The rolling trailing twelve-month net income per share illustrates this financial gap, where the -1.58 metric serves as the target level. The effective management of Leap Therapeutics, Inc. (LPTX), focusing on combination immunotherapy methods, aims to stabilize the company's fundamental metrics.

LPTX Leap Therapeutics, Inc. Net earnings per share for the last 12 months (07/04/2022 - 11/13/2025)

Summary analytical data breakdowns for Leap Therapeutics, Inc. (LPTX)

- share price and expert price forecast:
Fundamental valuation:LPTX - leaptx.com
Flagship merchandise of Leap Tx

This indicator represents the rolling annual profit per share, adjusted for issuance changes. The metric allows for the exclusion of one-off transactions and the precise identification of historical earnings extremes. By analyzing the trailing 12-month net income per share, an investor minimizes the risk of entering at peaks. For Leap Therapeutics, Inc. (LPTX), this figure reflects the cost efficiency of developing targeted antibodies. The high-tech nature of oncotherapy makes profit monitoring critical for assessing the capitalization of innovations.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)